Hepatitis: Liver-Injury Markers and What They Show

REVIEWED BY

William Maish, MD MBA MPH

Clinical Product Lead

Published

Last updated

Key takeaway:

Blood testing for hepatitis uses ALT, AST, bilirubin, and albumin to assess hepatocellular injury, bile processing, and synthetic capacity. Rising ALT (normal ~7–56) and AST (~10–40) signal liver cell damage, while elevated bilirubin (normal 0.1–1.2) is associated with jaundice and low albumin (<3.5) may reflect reduced protein synthesis—together staging inflammation and functional reserve alongside ALP, GGT, and serologies.

Read more →

Understand what your liver function testing results really mean

See your biomarkers in context with a comprehensive panel.

  • CLIA-certified labs
  • HIPAA compliant
  • Personalized health protocol
Book your test

Hepatitis and the liver-injury plus function picture

Hepatitis biomarkers are measurable clues in blood that show if a hepatitis virus is present, how active it is, and how the liver is responding. They fall into three broad groups. Viral identifiers detect the virus itself (HBsAg, HBeAg, HBV DNA, HCV RNA) or the immune system’s response to it (anti-HBs, anti-HBc IgM/IgG, anti-HBe, HCV antibodies). This profile maps exposure versus ongoing infection, recent versus long-standing disease, and contagiousness versus control. Injury signals reflect liver cell damage from inflammation (ALT, AST). Function markers show how well the liver is doing its jobs of bile handling and protein synthesis (bilirubin, albumin, clotting factors). Combined, these tests let clinicians find infection early, decide when to treat, monitor treatment effect, and confirm cure or control. They also help estimate the chance of complications from chronic inflammation and scarring (fibrosis). In short, hepatitis biomarker testing turns a hidden liver infection into a clear, trackable picture of the virus, the host response, and the organ’s health.

Join 150,000+ others building better health

Get the science behind better health, every week.

By clicking “Subscribe” you agree to our Terms of Service and Privacy Policy.

Reading a hepatitis-pattern liver panel

Hepatitis blood tests reveal how well the liver is handling its core jobs—processing nutrients, neutralizing toxins, making proteins, and managing bile flow. Together, aminotransferases (ALT, AST), bilirubin, and albumin show cell injury, bile obstruction, and the liver’s synthetic reserve, often before symptoms appear. Typical adult reference ranges are roughly: ALT 7–56, AST 10–40, bilirubin 0.1–1.2, albumin 3.5–5.0. In health, ALT and AST sit in the low-to-mid part of normal; bilirubin stays low; albumin is mid-to-high normal. Men often run slightly higher ALT/AST than women; pregnancy lowers albumin by dilution; newborns have higher bilirubin. When ALT/AST rise, it signals hepatocellular injury; when bilirubin rises, jaundice and itching can follow; albumin rarely runs high except with dehydration. Lower values carry different meanings. Low ALT/AST usually indicate little active liver-cell leakage, but can also reflect low muscle mass or vitamin B6 deficiency; in advanced “burned-out” hepatitis they may be deceptively normal despite severe disease. Low bilirubin is typically benign. Low albumin matters: it signals reduced hepatic protein synthesis or inflammation, and can lead to edema, ascites, and fatigue; in pregnancy, modest lowering is expected, while in children or elders it more strongly suggests illness or malnutrition. Big picture: these markers integrate with metabolism, immunity, clotting, hormones, and the gut–bile axis. Persistent abnormalities track risks of fibrosis, cirrhosis, portal hypertension, and liver cancer, and they intersect with kidney function, muscle health, alcohol, medications, and viral activity—making hepatitis testing central to long-term, system-wide health.

Test 100+ biomarkers from home

One blood draw. A full picture of your health, explained in plain language.

Book your test

What a liver panel reveals about hepatitis — and where serologies take over

Hepatitis blood testing provides a window into the health of your liver, a central organ for energy production, metabolism, detoxification, and immune regulation. When the liver is inflamed or injured—as in hepatitis—its ability to support these vital systems can be compromised. At Superpower, we assess four key biomarkers: ALT, AST, bilirubin, and albumin. Together, these markers help us understand how well your liver is functioning and whether it is under stress. ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are enzymes found in liver cells. When the liver is damaged by hepatitis, these enzymes leak into the bloodstream, signaling inflammation or injury. Bilirubin is a yellow pigment produced when red blood cells break down; the liver processes and clears it from the body. Elevated bilirubin can indicate that the liver’s filtering capacity is impaired. Albumin is a protein made by the liver that helps maintain fluid balance and transport hormones and nutrients. Low albumin levels may reflect reduced liver synthetic function, which can occur in chronic or severe hepatitis. Stable, healthy levels of ALT, AST, bilirubin, and albumin suggest that the liver is maintaining its essential roles in metabolism, detoxification, and protein synthesis, even in the presence of hepatitis. Significant changes in these markers can signal instability in liver function, which may affect energy, immunity, and overall system health. Interpretation of these biomarkers can be influenced by factors such as age, pregnancy, acute illness, certain medications, and laboratory assay differences. These variables are important to consider when evaluating liver health in the context of hepatitis.

Frequently Asked Questions

References

  1. Kwo PY, Cohen SM, Lim JK (2017). ACG clinical guideline: Evaluation of abnormal liver chemistries. *The American Journal of Gastroenterology*, *112*(1), 18-35. https://doi.org/10.1038/ajg.2016.517
  2. Polaris Observatory Collaborators. (2023). Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: A modelling study. *The Lancet Gastroenterology & Hepatology*, *8*(10), 879-907. https://doi.org/10.1016/S2468-1253(23)00197-8
  3. Polaris Observatory HCV Collaborators. (2022). Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: A modelling study. *The Lancet Gastroenterology & Hepatology*, *7*(5), 396-415. https://doi.org/10.1016/S2468-1253(21)00472-6
  4. Centers for Disease Control and Prevention. (n.d.). *About viral hepatitis*. https://www.cdc.gov/hepatitis/about/index.html
  5. Mayo Clinic. (n.d.). *Hepatitis - Symptoms and causes*. https://www.mayoclinic.org/diseases-conditions/hepatitis-a/symptoms-causes/syc-20367007

Led by doctors with 40 years of health and longevity expertise

Dr. Anant Vinjamoori

Dr. Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Dr. Leigh Erin Connealy

Dr. Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Dr. Robert Lufkin

Dr. Robert Lufkin, MD

Physician & UCLA Medical School Professor, NYT bestselling author

Dr. Abe Malkin

Dr. Abe Malkin, MD

Founder & Medical Director of Concierge MD

Membership 1
1 / 4

Your membership starts here

Annual 100+ biomarker panel

  • Data dashboard and digital twin
  • Upload past labs and connect wearables
  • Personalized health protocol
  • 24/7 care team access
  • AI companion for all health questions
  • Marketplace with additional solutions
$199
/year*Billed annually
Get started
HSA/FSA eligibleCancel anytimeResults in a week

*Pricing may vary for members in New York and New Jersey